Caxton Associates (New York)’s Emergent Biosolutions EBS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-50,265
| Closed | -$369K | – | 460 |
|
|
2023
Q2 | $369K | Sell |
50,265
-24,668
| -33% | -$181K | 0.05% | 313 |
|
|
2023
Q1 | $776K | Buy |
74,933
+61,908
| +475% | +$641K | 0.12% | 190 |
|
|
2022
Q4 | $154K | Sell |
13,025
-3,907
| -23% | -$46.1K | 0.01% | 379 |
|
|
2022
Q3 | $355K | Buy |
16,932
+213
| +1% | +$4.47K | 0.05% | 284 |
|
|
2022
Q2 | $519K | Buy |
+16,719
| New | +$519K | 0.05% | 249 |
|
|
2020
Q4 | – | Sell |
-2,637
| Closed | -$272K | – | 163 |
|
|
2020
Q3 | $272K | Sell |
2,637
-3,797
| -59% | -$392K | 0.03% | 203 |
|
|
2020
Q2 | $509K | Buy |
+6,434
| New | +$509K | 0.04% | 120 |
|